xixii Jean-Louis Pépin has received lecture fees or conference travel grants from ResMed, Philips, ITAMAR, Somnomed, Jazz Pharmaceuticals, Agiradom, and Bioprojet. He has also received unrestricted research funding from ResMed, Philips and Bioprojet. Jean-Louis Pépin is supported by: ‘My Way to Health’ via the French National Research Agency in the framework of the ‘Investissements d’avenir’ programme (ANR-15-IDEX-02) and the ‘e-health and integrated care and trajectories medicine and MIAI artificial intelligence’ Chairs of Excellence from the Grenoble Alpes University Foundation. Chapter 16.3 “Digital health innovations for optimisation and follow-up of therapy” was partially supported by MIAI@Grenoble Alpes (ANR-19-P3IA-0003). Jean-Louis Pépin would like to thank Alison Foote (Aide-à-la-Pub, Grenoble, France) for critically editing chapters 16.1 and 16.2 and improving English usage. Winfried Randerath reports receiving the following, outside the submitted work: consulting fees from Jazz Pharmaceuticals, Bioprojet and Philips payment or honoraria from Jazz Pharmaceuticals, Bioprojet, Philips Respironics and Desitin Pharma and support for attending meetings and/or travel from Jazz Pharmaceuticals, Bioprojet and Philips Respironics. Renata L. Riha has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Jazz Pharmaceuticals (one-off payment in 2021) has participated on a data safety monitoring board or advisory board for Jazz Pharmaceuticals (completed 2020) is co-director of Sleep Consultancy Ltd (ongoing, payments to business) and is the current Editor-in-Chief of the European Respiratory Review. All disclosures made outside the submitted work. Joerg Steier is the named inventor on a patent for an apparatus to treat snoring and sleep apnoea (King’s College London/Guy’s &St Thomas’ NHS Foundation Trust). Renaud Tamisier has received unrestricted research grants from ResMed, Vitalaire, Philips and the AGPMC Foundation, consultant fees from ResMed, Inspire, Navigant, Bioprojet and Jazz Pharmaceuticals, and travel grants from Agiradom. Renaud Tamisier is supported by: ‘My Way to Health’ via the French National Research Agency in the framework of the ‘Investissements d’avenir’ programme (ANR-15-IDEX-02) and the ‘e-health and integrated care and trajectories medicine and MIAI artificial intelligence’ Chairs of Excellence from the Grenoble Alpes University Foundation. Chapters 16.2 and 16.3 were was partially supported by MIAI@Grenoble Alpes (ANR-19-P3IA-0003). Renaud Tamisier would like to thank Alison Foote (Aide-à-la-Pub, Grenoble, France) for critically editing chapters 16.1 and 16.2 and improving English usage. Luigi Taranto-Montemurro is Chief Scientific Officer of Apnimed and has a financial interest in the company (Apnimed is a company that develops pharmacological therapies for sleep apnoea). Luigi Taranto-Montemurro’s interests are reviewed and managed by Brigham and Women’s Hospital and Partners HealthCare, in accordance with their conflict of interest policies.